Name | Initial efficacy a | Half-life a | Decay shape a | Vaccine coverage |
---|---|---|---|---|
Reference | EPI: 62.5 %, 6-9 months: 79.2 % | EPI : 1.12 year, 6-9 months: 1.12 year | Exponential | EPI: DTP3, 6-9 months: 75 % of DTP3 |
B | Reference | Reference | Reference | Increase 6-9 months to EPI coverage |
C | Increase (EPI: 80.3 %, 6-9 months: 84.8 %) | Reference | Reference | Reference |
D | Decrease (EPI: 39.5 %, 6-9 months: 67.3. %) | Reference | Reference | Reference |
E | Reference | Increase (EPI : 3 year, 6-9 months: 3 year) | Reference | Reference |
F | Decrease (EPI: 39.5 %, 6-9 months: 67.3. %) | Increase (EPI : 3 year, 6-9 months: 3 year) | Reference | Reference |
G | Increase (EPI: 80.3 %, 6-9 months: 84.8 %) | Increase (EPI : 3 year, 6-9 months: 3 year) | Reference | Reference |